Mereo BioPharma

As part of our mission to improve the lives of those with rare diseases, we are joining @rarediseasesint to call for Universal Healthcare Coverage for rare diseases. For the 300mil+ people with rare diseases, access to healthcare services is vital to their quality of life #UHCDay

The TIGIT Axis Therapies Digital Summit begins today, exploring the potential for next-generation TIGIT therapies. We are excited to hear from Suba Krishnan, SVP at Mereo, tomorrow @ 14.00 (EST) to share preliminary findings from Etigilimab + Nivolumab. bit.ly/3iLr9ss

Today is World #COPD Day, an opportunity for us all to support @GOLD_COPD’s “Your Lungs for Life" campaign. Testing for underlying genetic causes of COPD e.g. #AATD #Alpha1 can support understanding of contributing factors to COPD, improving lung health & protecting those at risk

Join our CEO Denise Scots-Knight for a fireside chat at the @Jefferies London Healthcare Conference on Nov 15 @ 12:55pm GMT / 07:55am ET. A live audio webcast of can be accessed at mereobiopharma.com/investors. #JefferiesHealthcare

We are pleased to announce the FDA has granted Fast Track designation for alvelestat for the treatment of AATD-LD, recognizing alvelestat as a potentially first-in-class oral neutrophil elastase inhibitor. We look forward to a R&D update on Oct 31 View PR: bit.ly/3CBJE93

We are pleased to share updated clinical data for etigilimab + nivolumab in select recurrent advanced/metastatic solid tumors. View press release: bit.ly/3RBKfhp #TIGIT

A great session presenting biomarker analysis of etig + nivo from the ACTIVATE study at #ESMO2022. We are encouraged by the totality of biomarker data which may provide a roadmap for future clinical studies of etigilimab.

We are looking forward to presentations from our partner @Ultragenyx on the Orbit & ASTEROID studies in #OsteogenesisImperfecta at #ASBMR2022 as well as sharing more data from the #IMPACTsurvey bit.ly/3Bq729d

We are excited to share biomarker analysis of etigilimab + nivolumab in select recurrent advanced/metastatic solid tumors at the upcoming #ESMO2022. The poster will be available to view from 9am Central European Time, Sat 10 Sept.

We also had a talk from Dr Davina Ford and Dr Jennie Walsh who gave an overview of the Sheffield Transition process into Adult Services. Dr Ruth Kingshott also shared some resources on sleep, the BBS will update our website to include these. #oi2022

OIF CEO Tracy Hart is currently attending the #OI2022 international OI meeting in Sheffield, UK! Yesterday, Tracy joined @BrittleBoneUK CEO Patricia Osborne and @OIFE_OI President Ingunn Westerheim on a panel to discuss the value and importance of patient engagement.

We had a fantastic first day at @#oi2022! @OI2022tweets. Key information from today: •Our CEO Patricia gave an overview of the BBS alongside and Ingunn Westerheim from @OIFE_OI and Tracey Hart from @OIFoundation

Join our CEO Denise Scots-Knight for a presentation at the @Jefferies Healthcare Conference, today @ 09:30 AM ET. A live audio webcast of the presentation can be accessed through the Investors section of our website at mereobiopharma.com/investors. @ScotsKnight2

We are announcing the appointment of Dr. Abdul Mullick to our Board of Directors. His experience developing & commercializing rare disease products will be invaluable as we continue our journey to bring new treatments to those with rare diseases & cancer bit.ly/3sG0Whc

Mereo is pleased to report positive top-line Data from “ASTRAEUS” a Phase 2 trial of alvelestat in AATD. Join us at 10:30 ET for a conference call to discuss the data in more detail. See the press release for full dial-in details bit.ly/3vVGiLZ @ScotsKnight2

Join Mereo in wearing something yellow to celebrate #wishboneday. #Wishboneday recognizes the voices and incredible contributions of people living with OI. We are proud to add our voices to those of the OI community to help raise awareness. #OI @OIFoundation @OIFE_OI

Mereo is looking forward to the publication of updated data from ACTIVATE, a phase 1b/2 study of etigilimab + nivolumab in solid tumors at the 2022 American Society of Clinical Oncology Annual Meeting meetings.asco.org/abstracts-pres… #ASCO22 #TIGIT

Our partner @Ultragenyx has dosed the first patient in the pivotal ORBIT study, a seamless Phase 2/3 study of setrusumab for the treatment of #OsteogenesisImperfecta. A very important step towards bringing potential new treatments to patients #OI bit.ly/3Ml7Xv4

We are pleased to report full year 2021 financial results and recent company highlights. In 2021 we continued to execute on all fronts and made substantial progress across our pipeline. Read our press release for more detail: bit.ly/386WDUC

We are sharing an update on our alvelestat (MPH966) program at our upcoming virtual R&D Day. Expect to hear from Key Opinion Leaders and members of Mereo’s management team on progress for AATD, GVHD BOS and COVID 19. Join the webcast at 10 AM ET here: bit.ly/3I75ySi